Teledyne Photometrics describe SMi’s products and the role that their imaging systems play in them.
Read More
Ronnie Andrews offers SMi 35+ years of senior leadership experience in Life Sciences Tools and Molecular Diagnostics sectors.
Read More
SMi is delighted to have been recognised as the Best Emerging Pharma Company / Startup in this year’s awards.
Read More
Knight Optical describes how they worked with SMi’s engineers to develop custom optics for volume manufacture.
Read More
Single molecule imaging allows scientists to understand the function of enzymes with unprecedented detail and to utilise them as reagents in novel single molecule assays. Here, we explore the unique value that this offers.
Read More
SMi is delighted to be short listed as a finalist in the category of Best Emerging Pharma Company/Start Up.
Read More
SMi becomes ISO 13485 certified following its recent audit by the British Standards Institution.
Read More
Being able to detect analytes is a critical aspect of drug discovery and diagnosis. Here we show how single molecule counting can increase assay sensitivity.
Read More
SMi is delighted to continue expanding its portfolio with the granting of another patent.
Read More
SMi Systems is developing a commercial analytics platform that automates single-molecule detection and analysis. Here we describe why single-molecule measurements are likely to become the go-to approach when developing novel drugs and vaccines.
Read More
SMi Systems is developing a commercial analytics platform that automates single-molecule detection and analysis. Here we describe why single-molecule measurements are likely to become the go-to approach when developing novel drugs and vaccines.
Read More
SMi has been contracted to develop another Quality Control assay that enables single molecule detection of contaminating infectious particles.
Read More
SMi expands its IP portfolio further by receiving a Notice of Allowance from the US Patent and Trademark Office for its high throughput single molecule imaging platform.
Read More